The global cell therapy market size is calculated at USD 7.43 billion in 2025 and is forecasted to reach around USD 47.72 billion by 2034, accelerating at a CAGR of 22.96% from 2025 to 2034. The North America cell therapy market size surpassed USD 3.56 billion in 2024 and is expanding at a CAGR of 23.07% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell Therapy Market, by Use Type
8.1.1. Clinical use
8.1.1.1. Market Revenue and Forecast
8.1.2. Research use
8.1.2.1. Market Revenue and Forecast
9.1. Cell Therapy Market, by Therapy Type
9.1.1. Autologous Therapies
9.1.1.1. Market Revenue and Forecast
9.1.2. Allogenic Therapies
9.1.2.1. Market Revenue and Forecast
10.1. Cell Therapy Market, by End User
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Diagnostic centers
10.1.2.1. Market Revenue and Forecast
10.1.3. Clinics
10.1.3.1. Market Revenue and Forecast
10.1.4. Research institutes
10.1.4.1. Market Revenue and Forecast
10.1.5. Regenerative medicine centers
10.1.5.1. Market Revenue and Forecast
10.1.6. Others
10.1.6.1. Market Revenue and Forecast
11.1. Cell Therapy Market, by Technology
11.1.1. Viral Vector Technology
11.1.1.1. Market Revenue and Forecast
11.1.2. Genome Editing Technology
11.1.2.1. Market Revenue and Forecast
11.1.3. Somatic Cell Technology
11.1.3.1. Market Revenue and Forecast
11.1.4. Cell Immortalization Technology
11.1.4.1. Market Revenue and Forecast
11.1.5. Cell Plasticity Technology
11.1.5.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Use Type
12.1.2. Market Revenue and Forecast, by Therapy Type
12.1.3. Market Revenue and Forecast, by End User
12.1.4. Market Revenue and Forecast, by Technology
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Use Type
12.1.5.2. Market Revenue and Forecast, by Therapy Type
12.1.5.3. Market Revenue and Forecast, by End User
12.1.5.4. Market Revenue and Forecast, by Technology
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Use Type
12.1.6.2. Market Revenue and Forecast, by Therapy Type
12.1.6.3. Market Revenue and Forecast, by End User
12.1.6.4. Market Revenue and Forecast, by Technology
12.2. Europe
12.2.1. Market Revenue and Forecast, by Use Type
12.2.2. Market Revenue and Forecast, by Therapy Type
12.2.3. Market Revenue and Forecast, by End User
12.2.4. Market Revenue and Forecast, by Technology
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Use Type
12.2.5.2. Market Revenue and Forecast, by Therapy Type
12.2.5.3. Market Revenue and Forecast, by End User
12.2.5.4. Market Revenue and Forecast, by Technology
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Use Type
12.2.6.2. Market Revenue and Forecast, by Therapy Type
12.2.6.3. Market Revenue and Forecast, by End User
12.2.6.4. Market Revenue and Forecast, by Technology
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Use Type
12.2.7.2. Market Revenue and Forecast, by Therapy Type
12.2.7.3. Market Revenue and Forecast, by End User
12.2.7.4. Market Revenue and Forecast, by Technology
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Use Type
12.2.8.2. Market Revenue and Forecast, by Therapy Type
12.2.8.3. Market Revenue and Forecast, by End User
12.2.8.4. Market Revenue and Forecast, by Technology
12.3. APAC
12.3.1. Market Revenue and Forecast, by Use Type
12.3.2. Market Revenue and Forecast, by Therapy Type
12.3.3. Market Revenue and Forecast, by End User
12.3.4. Market Revenue and Forecast, by Technology
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Use Type
12.3.5.2. Market Revenue and Forecast, by Therapy Type
12.3.5.3. Market Revenue and Forecast, by End User
12.3.5.4. Market Revenue and Forecast, by Technology
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Use Type
12.3.6.2. Market Revenue and Forecast, by Therapy Type
12.3.6.3. Market Revenue and Forecast, by End User
12.3.6.4. Market Revenue and Forecast, by Technology
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Use Type
12.3.7.2. Market Revenue and Forecast, by Therapy Type
12.3.7.3. Market Revenue and Forecast, by End User
12.3.7.4. Market Revenue and Forecast, by Technology
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Use Type
12.3.8.2. Market Revenue and Forecast, by Therapy Type
12.3.8.3. Market Revenue and Forecast, by End User
12.3.8.4. Market Revenue and Forecast, by Technology
12.4. MEA
12.4.1. Market Revenue and Forecast, by Use Type
12.4.2. Market Revenue and Forecast, by Therapy Type
12.4.3. Market Revenue and Forecast, by End User
12.4.4. Market Revenue and Forecast, by Technology
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Use Type
12.4.5.2. Market Revenue and Forecast, by Therapy Type
12.4.5.3. Market Revenue and Forecast, by End User
12.4.5.4. Market Revenue and Forecast, by Technology
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Use Type
12.4.6.2. Market Revenue and Forecast, by Therapy Type
12.4.6.3. Market Revenue and Forecast, by End User
12.4.6.4. Market Revenue and Forecast, by Technology
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Use Type
12.4.7.2. Market Revenue and Forecast, by Therapy Type
12.4.7.3. Market Revenue and Forecast, by End User
12.4.7.4. Market Revenue and Forecast, by Technology
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Use Type
12.4.8.2. Market Revenue and Forecast, by Therapy Type
12.4.8.3. Market Revenue and Forecast, by End User
12.4.8.4. Market Revenue and Forecast, by Technology
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Use Type
12.5.2. Market Revenue and Forecast, by Therapy Type
12.5.3. Market Revenue and Forecast, by End User
12.5.4. Market Revenue and Forecast, by Technology
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Use Type
12.5.5.2. Market Revenue and Forecast, by Therapy Type
12.5.5.3. Market Revenue and Forecast, by End User
12.5.5.4. Market Revenue and Forecast, by Technology
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Use Type
12.5.6.2. Market Revenue and Forecast, by Therapy Type
12.5.6.3. Market Revenue and Forecast, by End User
12.5.6.4. Market Revenue and Forecast, by Technology
13.1. Kolon TissueGene Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. JCR Pharmaceuticals Co. Ltd
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Castle Creek Biosciences Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Anterogen Co. Ltd
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. The Future of Biotechnology
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Celgene Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Tameika Cell Technologies Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Cells for Cells
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. MEDIPOST
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. NuVasive Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample